JP2014513712A5 - - Google Patents

Download PDF

Info

Publication number
JP2014513712A5
JP2014513712A5 JP2014510872A JP2014510872A JP2014513712A5 JP 2014513712 A5 JP2014513712 A5 JP 2014513712A5 JP 2014510872 A JP2014510872 A JP 2014510872A JP 2014510872 A JP2014510872 A JP 2014510872A JP 2014513712 A5 JP2014513712 A5 JP 2014513712A5
Authority
JP
Japan
Prior art keywords
asenapine maleate
monoclinic
stable
less
finely divided
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014510872A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014513712A (ja
JP6014656B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2012/000450 external-priority patent/WO2012156677A1/en
Publication of JP2014513712A publication Critical patent/JP2014513712A/ja
Publication of JP2014513712A5 publication Critical patent/JP2014513712A5/ja
Application granted granted Critical
Publication of JP6014656B2 publication Critical patent/JP6014656B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014510872A 2011-05-18 2012-05-18 化合物の多形体 Active JP6014656B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161487495P 2011-05-18 2011-05-18
US61/487,495 2011-05-18
PCT/GB2012/000450 WO2012156677A1 (en) 2011-05-18 2012-05-18 A stable micronised monoclinic form of asenapine maleate and its synthesis

Publications (3)

Publication Number Publication Date
JP2014513712A JP2014513712A (ja) 2014-06-05
JP2014513712A5 true JP2014513712A5 (enExample) 2015-07-02
JP6014656B2 JP6014656B2 (ja) 2016-10-25

Family

ID=46168537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014510872A Active JP6014656B2 (ja) 2011-05-18 2012-05-18 化合物の多形体

Country Status (5)

Country Link
US (1) US9505771B2 (enExample)
EP (1) EP2709616B1 (enExample)
JP (1) JP6014656B2 (enExample)
ES (1) ES2665843T3 (enExample)
WO (1) WO2012156677A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2582704A4 (en) * 2010-06-18 2014-04-02 Reddys Lab Ltd Dr Asenapine MALEATE
US10085971B2 (en) * 2016-08-22 2018-10-02 Navinta Iii Inc Pharmaceutical solution of asenapine for sublingual or buccal use
CN110087641B (zh) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
BR112020026099A2 (pt) 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico que contém asenapina
CN118806732A (zh) 2018-06-20 2024-10-22 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
US20250032451A1 (en) * 2021-11-24 2025-01-30 Oakwood Laboratories, Llc Microsphere formulations comprising asenapine and methods for making and using the same
WO2026095022A1 (ja) * 2024-11-01 2026-05-07 大鵬薬品工業株式会社 キノリン置換化合物の結晶

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (nl) 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
ATE167057T1 (de) 1994-03-02 1998-06-15 Akzo Nobel Nv Sublinguales oder bukkales arzneimittel
ES2290095T3 (es) * 2000-12-27 2008-02-16 Ares Trading S.A. Microparticulas lipidicas por micronizacion criogenica.
US7872147B2 (en) 2005-04-07 2011-01-18 N. V. Organon Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
KR101422843B1 (ko) 2005-04-07 2014-07-24 머크 샤프 앤 도메 비.브이. 아세나핀 말레에이트의 결정형
US7741358B2 (en) * 2005-04-14 2010-06-22 N.V. Organon Crystal form of asenapine maleate
US7750167B2 (en) 2006-07-05 2010-07-06 N.V. Organon Process for the preparation of asenapine and intermediate products used in said process
WO2008148515A1 (en) * 2007-06-05 2008-12-11 Synthon B.V. Intranasal administration of asenapine and pharmaceutical compositions therefor
EP2582704A4 (en) * 2010-06-18 2014-04-02 Reddys Lab Ltd Dr Asenapine MALEATE
EP2598496B1 (en) * 2010-07-29 2014-03-19 Laboratorios Lesvi, S.L. Novel process for the preparation of asenapine
WO2012038975A2 (en) 2010-09-22 2012-03-29 Msn Laboratories Limited Process for the preparation of (3ars,12brs)-5-chloro-2-methyl-2,3,3a12b-tetrahydro-1hdibenzo[2,3:6,7] oxepino [4,5-c]pyrrole maleate and it's pharmaceutical composition thereof
WO2012066565A2 (en) * 2010-11-16 2012-05-24 Cadila Healthcare Limited Asenapine maleate amorphous and crystalline form and process for preparation thereof
EP2468750A1 (en) * 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Polymorphic forms of asenapine maleate and processes for their preparation
ITMI20110734A1 (it) * 2011-05-02 2012-11-03 Olon Spa Sali cristallini di asenapina
WO2012156676A1 (en) * 2011-05-18 2012-11-22 Laboratorios Lesvi S.L. Monoclinic crystalline form of asenapine maleate with a specific particle size distribution

Similar Documents

Publication Publication Date Title
JP2013237682A5 (enExample)
WO2013132457A3 (en) Nanocrystalline solid dispersion compositions and process of preparation thereof
JP2012176975A5 (enExample)
AR122183A2 (es) Proceso para la preparación de una forma cristalina de un inhibidor de pde4, forma cristalina, composición farmacéutica para inhalación, usos y solvato
NZ616637A (en) Preparation of high-purity gadobutrol
TN2014000356A1 (en) Heterocyclyl compounds as mek inhibitors
NZ591914A (en) Naphthylacetic acids
IN2014DN09352A (enExample)
JP2014114295A5 (enExample)
IN2014DN09348A (enExample)
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
JP2011522827A5 (enExample)
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
WO2010018112A3 (en) Monoaryl aminotetralines
JP2015500331A5 (enExample)
JP2017519015A5 (enExample)
JP2016510768A5 (enExample)
ES2606307T3 (es) Producto de co-micronización que comprende acetato de ulipristal
RU2016100972A (ru) Стабильная кристаллическая форма типирацила гидрохлорида и способ ее кристаллизации
IN2014DN09347A (enExample)
ES2597784T3 (es) Combinación de extracto de raíz de valeriana y aceite de lavanda para utilizar en el tratamiento de trastornos del sueño
CA2920410C (en) Thienopiperidine derivative and use thereof
NZ601920A (en) New crystalline form of a cyclopropyl benzamide derivative
JP2015516425A5 (enExample)
CN104829603A (zh) A晶型依匹唑派盐酸盐及其制备方法